1. Home
  2. NAMS vs HCI Comparison

NAMS vs HCI Comparison

Compare NAMS & HCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • HCI
  • Stock Information
  • Founded
  • NAMS 2019
  • HCI 2006
  • Country
  • NAMS Netherlands
  • HCI United States
  • Employees
  • NAMS N/A
  • HCI 552
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • HCI Property-Casualty Insurers
  • Sector
  • NAMS Health Care
  • HCI Finance
  • Exchange
  • NAMS Nasdaq
  • HCI Nasdaq
  • Market Cap
  • NAMS 3.1B
  • HCI 2.5B
  • IPO Year
  • NAMS N/A
  • HCI N/A
  • Fundamental
  • Price
  • NAMS $32.86
  • HCI $194.70
  • Analyst Decision
  • NAMS Strong Buy
  • HCI Strong Buy
  • Analyst Count
  • NAMS 9
  • HCI 4
  • Target Price
  • NAMS $41.89
  • HCI $181.25
  • AVG Volume (30 Days)
  • NAMS 974.1K
  • HCI 173.7K
  • Earning Date
  • NAMS 11-05-2025
  • HCI 11-06-2025
  • Dividend Yield
  • NAMS N/A
  • HCI 0.82%
  • EPS Growth
  • NAMS N/A
  • HCI N/A
  • EPS
  • NAMS N/A
  • HCI 11.47
  • Revenue
  • NAMS $64,006,000.00
  • HCI $775,545,000.00
  • Revenue This Year
  • NAMS N/A
  • HCI $19.75
  • Revenue Next Year
  • NAMS $1.67
  • HCI $8.24
  • P/E Ratio
  • NAMS N/A
  • HCI $17.03
  • Revenue Growth
  • NAMS 762.15
  • HCI 9.67
  • 52 Week Low
  • NAMS $14.06
  • HCI $91.06
  • 52 Week High
  • NAMS $34.62
  • HCI $199.00
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 72.18
  • HCI 73.42
  • Support Level
  • NAMS $27.15
  • HCI $184.23
  • Resistance Level
  • NAMS $34.59
  • HCI $193.30
  • Average True Range (ATR)
  • NAMS 1.47
  • HCI 5.67
  • MACD
  • NAMS 0.50
  • HCI 0.39
  • Stochastic Oscillator
  • NAMS 73.37
  • HCI 100.00

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About HCI HCI Group Inc.

HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.

Share on Social Networks: